The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2019 | Lessons learned from the CLL CLARITY study and ongoing follow-up
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses the lessons that we have learned from the Bloodwise Trials Acceleration Programme (TAP) CLARITY study (ISCRTN13751862), which investigated venetoclax in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Dr Munir also discusses the ongoing follow-up analysis to see how durable MRD negativity was. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
